Detailed genetic and functional analysis of the hDMDdel52/ mdx mouse model
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Duchenne muscular dystrophy (DMD) is a severe, progressive neuromuscular disorder caused by reading frame disrupting mutations in the DMD gene leading to absence of functional dystrophin. Antisense oligonucleotide (AON)-mediated exon skipping is a therapeutic approach aimed at restoring the reading frame at the pre-mRNA level, allowing the production of internally truncated partly functional dystrophin proteins. AONs work in a sequence specific manner, which warrants generating humanized mouse models for preclinical tests. To address this, we previously generated the hDMDdel52/mdx mouse model using transcription activator like effector nuclease (TALEN) technology. This model contains mutated murine and human DMD genes, and therefore lacks mouse and human dystrophin resulting in a dystrophic phenotype. It allows preclinical evaluation of AONs inducing the skipping of human DMD exons 51 and 53 and resulting in restoration of dystrophin synthesis. Here, we have further characterized this model genetically and functionally. We discovered that the hDMD and hDMDdel52 transgene is present twice per locus, in a tail-to-tail-orientation. Long-read sequencing revealed a partial deletion of exon 52 (first 25 bp), and a 2.3 kb inversion in intron 51 in both copies. These new findings on the genomic make-up of the hDMD and hDMDdel52 transgene do not affect exon 51 and/or 53 skipping, but do underline the need for extensive genetic analysis of mice generated with genome editing techniques to elucidate additional genetic changes that might have occurred. The hDMDdel52/mdx mice were also evaluated functionally using kinematic gait analysis. This revealed a clear and highly significant difference in overall gait between hDMDdel52/mdx mice and C57BL6/J controls. The motor deficit detected in the model confirms its suitability for preclinical testing of exon skipping AONs for human DMD at both the functional and molecular level.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Exemplary here could be the hDMDdel52/mdx mouse, which carries the entire human DMD gene with a partial deletion of exon 52 that prevents expression of Dp427 and Dp140 (Veltrop et al., 2018; Yavas et al., 2020).”
From Understanding Duchenne muscular dystrophy-associated brain pathology (2025) · cites this paper as Yavas et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
The Molecular Basis of Muscular Dystrophy in the mdx Mouse: a Point Mutation
Sicinski, P., Geng, Y., Ryder-Cook, A. S., Barnard, E. A., Darlison, M. G., & Barnard, P. J. (1989) · Science · doi:10.1126/science.2662404 · Cited by 1,276
Research works printed but not linked: 32
- SJ Moat, 2013, Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK), European journal of human genetics: EJHG, 21, 1049, 10.1038/ejhg.2012.301 · DOI · Paper page
- QQ Gao, 2015, The Dystrophin Complex: Structure, Function, and Implications for Therapy, Compr Physiol, 5, 1223
- EP Rader, 2016, Role of dystroglycan in limiting contraction-induced injury to the sarcomeric cytoskeleton of mature skeletal muscle, 113, 10992
- M Pane, 2013, Early neurodevelopmental assessment in Duchenne muscular dystrophy, Neuromuscular disorders: NMD, 23, 451, 10.1016/j.nmd.2013.02.012 · DOI
- Y Shimizu-Motohashi, 2016, Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trials, American journal of translational research, 8, 2471
- F Muntoni, 2011, Targeting RNA to treat neuromuscular disease, Nature reviews Drug discovery, 10, 621, 10.1038/nrd3459 · DOI
- F Muntoni, 2003, Dystrophin and mutations: one gene, several proteins, multiple phenotypes, The Lancet Neurology, 2, 731, 10.1016/S1474-4422(03)00585-4 · DOI · Paper page
- RG Hendriksen, 2015, A possible role of dystrophin in neuronal excitability: a review of the current literature, Neurosci Biobehav Rev, 51, 255, 10.1016/j.neubiorev.2015.01.023 · DOI
- A Aartsma-Rus, 2006, Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule, Muscle & nerve, 34, 135, 10.1002/mus.20586 · DOI · Paper page
- CL Bladen, 2015, The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations, Human mutation, 36, 395, 10.1002/humu.22758 · DOI · Paper page
- R Maruyama, 2018, Creation of DMD Muscle Cell Model Using CRISPR-Cas9 Genome Editing to Test the Efficacy of Antisense-Mediated Exon Skipping, Methods Mol Biol, 1828, 165, 10.1007/978-1-4939-8651-4_10 · doi:10.1007/978-1-4939-8651-4_10
- U Akpulat, 2018, Shorter Phosphorodiamidate Morpholino Splice-Switching Oligonucleotides May Increase Exon-Skipping Efficacy in DMD, Mol Ther Nucleic Acids, 13, 534, 10.1016/j.omtn.2018.10.002 · DOI
- JG Andrews, 2018, Duchenne and Becker muscular dystrophy in adolescents: current perspectives, Adolesc Health Med Ther, 9, 53, 10.2147/AHMT.S125739 · DOI
- A Nakamura, 2016, Deletion of exons 3–9 encompassing a mutational hot spot in the DMD gene presents an asymptomatic phenotype, indicating a target region for multiexon skipping therapy, Journal of human genetics, 61, 663, 10.1038/jhg.2016.28 · DOI
- L Bello, 2016, DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study, Neurology, 87, 401, 10.1212/WNL.0000000000002891 · DOI · Paper page
- L Bello, 2016, Genetic diagnosis as a tool for personalized treatment of Duchenne muscular dystrophy, Acta myologica: myopathies and cardiomyopathies: official journal of the Mediterranean Society of Myology, 35, 122
- A Aartsma-Rus, 2009, Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations, 30, 293
- KR Lim, 2017, Eteplirsen in the treatment of Duchenne muscular dystrophy, Drug design, development and therapy, 11, 533, 10.2147/DDDT.S97635 · DOI · Paper page
- A Aartsma-Rus, 2018, Why dystrophin quantification is key in the eteplirsen saga, Nature reviews Neurology, 14, 454, 10.1038/s41582-018-0033-8 · doi:10.1038/s41582-018-0033-8
- A Aartsma-Rus, 2020, The 10th Oligonucleotide Therapy Approved: Golodirsen for Duchenne Muscular Dystrophy, Nucleic Acid Ther, 10.1089/nat.2020.0845 · DOI
- A Aartsma-Rus, 2019, A Sequel to the Eteplirsen Saga: Eteplirsen Is Approved in the United States but Was Not Approved in Europe, Nucleic Acid Ther, 29, 13, 10.1089/nat.2018.0756 · DOI
- S Dhillon, 2020, Viltolarsen: First Approval, Drugs, 80, 1027, 10.1007/s40265-020-01339-3 · DOI · Paper page
- JW McGreevy, 2015, Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy, 8, 195
- PA t Hoen, 2008, Generation and characterization of transgenic mice with the full-length human DMD gene, J Biol Chem, 283, 5899, 10.1074/jbc.M709410200 · DOI
- M Veltrop, 2018, A dystrophic Duchenne mouse model for testing human antisense oligonucleotides, PLoS One, 13, e0193289, 10.1371/journal.pone.0193289 · DOI · Paper page
- M Veltrop, 2013, Generation of embryonic stem cells and mice for duchenne research, PLoS Curr, 5
- C Beekman, 2018, Use of capillary Western immunoassay (Wes) for quantification of dystrophin levels in skeletal muscle of healthy controls and individuals with Becker and Duchenne muscular dystrophy, PLoS One, 13, e0195850, 10.1371/journal.pone.0195850 · DOI · Paper page
- RC Verheul, 2016, Digital Droplet PCR for the Absolute Quantification of Exon Skipping Induced by Antisense Oligonucleotides in (Pre-)Clinical Development for Duchenne Muscular Dystrophy, PLoS One, 11, e0162467, 10.1371/journal.pone.0162467 · DOI
- I Gazzoli, 2016, Non-sequential and multi-step splicing of the dystrophin transcript, RNA biology, 13, 290, 10.1080/15476286.2015.1125074 · DOI · Paper page
- NA Datson, 2020, Using a State-of-the-Art Toolbox to Evaluate Molecular and Functional Readouts of Antisense Oligonucleotide-Induced Exon Skipping in mdx Mice, Nucleic Acid Ther, 30, 50, 10.1089/nat.2019.0824 · DOI
- 2019, Cell-Penetrating Peptide Conjugates of Steric Blocking Oligonucleotides as Therapeutics for Neuromuscular Diseases from a Historical Perspective to Current Prospects of Treatment, 29, 1
- CS Young, 2017, Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR/Cas9 Gene Editing Therapy, J Neuromuscul Dis, 4, 139, 10.3233/JND-170218 · DOI
Cited by
Understanding Duchenne muscular dystrophy-associated brain pathology
Verhaeg, M. A. T., Govaarts, R., & van Putten, M. (2025) · Disease Models & Mechanisms · doi:10.1242/dmm.052302 · Cited by 5
Metadata
- Authors
- Yavas, A., Weij, R., van Putten, M., Kourkouta, E., Beekman, C., Puoliväli, J., Bragge, T., Ahtoniemi, T., Knijnenburg, J., Hoogenboom, M. E., Ariyurek, Y., Aartsma-Rus, A., van Deutekom, J., & Datson, N.
- ORCID
- Yavas, Alper
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2020-12-23
- Volume
- 15
- Issue
- 12
- Pages
- e0244215
- ISSN
- 1932-6203
- Cited by
- 33
- References
- 2
- Language
- en
- Funders
- BioMarin Pharmaceutical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Detailed genetic and functional analysis of the hDMDdel52/ mdx mouse model. https://app.cochat.ai/papers/10.1371/journal.pone.0244215
- The paper
- Yavas, A., Weij, R., van Putten, M., Kourkouta, E., Beekman, C., Puoliväli, J., Bragge, T., Ahtoniemi, T., Knijnenburg, J., Hoogenboom, M. E., Ariyurek, Y., Aartsma-Rus, A., van Deutekom, J., & Datson, N. (2020). Detailed genetic and functional analysis of the hDMDdel52/ mdx mouse model. PLOS ONE. https://doi.org/10.1371/journal.pone.0244215
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.